A Non-Interventional Post-Authorisation Safety Study (PASS) of Inotuzumab Ozogamicin to Characterize Complications Post-Hematopoietic Stem Cell Transplantation (HSCT) Following Inotuzumab Ozogamicin Treatment in Adult and Pediatric Patients with B-Cell Precursor Acute Lymphoblastic Leukemia (ALL).

ENCePP Code of conduct

No

Data sources

• Data sources (types):
  Disease registry

Use of a Common Data Model (CDM)

• CDM mapping:
  No

Data quality specifications

• Check conformance:
  Unknown
• Check completeness:
  Unknown
• Check stability:
  Unknown
• Check logical consistency:
  Unknown

Data characterisation

• Data characterisation conducted:
  No